Experiences and lessons learned from 29 HPV vaccination programs implemented in 19 low and middle-income countries, 2009-2014

BMC Health Services Research

Volumn 16, Issue 1, 2016, Pages 1-10

  Ladner, Joël ^a   Besson, Marie Hélène ^b   Audureau, Etienne ^c   Rodrigues, Mariana ^b   Saba, Joseph ^b  

^a HÔPITAL CHARLES NICOLLE   (France)

^b Axios International   (France)

^c UNIVERSITÉ PARIS EST CRÉTEIL   (France)

Author keywords

Developing countries; Human papillomavirus vaccine type 16 L1 18; Immunization uterine cervical neoplasms; Preventive health services; Program evaluation; Vaccination; Vaccines

Indexed keywords

WART VIRUS VACCINE;

ADOLESCENT; ADULT; DEVELOPING COUNTRY; EARLY CANCER DIAGNOSIS; FEMALE; GOVERNMENT; HUMAN; ORGANIZATION AND MANAGEMENT; PAPILLOMAVIRUS INFECTIONS; PREVENTIVE HEALTH SERVICE; PROGRAM DEVELOPMENT; QUESTIONNAIRE; UTERINE CERVICAL NEOPLASMS;

ADOLESCENT; ADULT; DEVELOPING COUNTRIES; EARLY DETECTION OF CANCER; EFFICIENCY, ORGANIZATIONAL; FEMALE; GOVERNMENT PROGRAMS; HUMANS; IMMUNIZATION PROGRAMS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PREVENTIVE HEALTH SERVICES; PROGRAM DEVELOPMENT; SURVEYS AND QUESTIONNAIRES; UTERINE CERVICAL NEOPLASMS;

EID: 84992049109     PISSN: None     EISSN: 14726963     Source Type: Journal    
DOI: 10.1186/s12913-016-1824-5     Document Type: Article

References (33)

1. Ferlay J, Shin H, Baray F, Forman D, Mathers C, Parkin DM. Estimate of worldwide burden of in 2008. Globocan 2008. Int J Cancer. 2010;127:2893-917.
2. Oh JK, Weiderpass E. Incfection and cancer: global distribution and burden of diseases. Ann Glob Health. 2014;80:384-92.
3. Forman D, de Martel C, Lacey CJ, Soerjomataram I, Lortet-Tieulent J, Bruni L, et al. Global burden of human papillomavirus and related diseases. Vaccine. 2012;30(S5):F12-23.
4. Broker TR. Global prevention and management of human papillomavirus related diseases: the pressing challenges and the compelling opportunities. Vaccine. 2012;30(S5):7-10.
5. Arbyn M, Castellsagué X, de Sanjosé S, Bruni L, Saraiya M, Bray F, et al. Worldwide burden of cervical cancer in 2008. Ann Oncol. 2011;22:2675-86.
6. Yang BH, Bray FI, Parkin DM, Sellors JW, Zhang ZF. Cervical cancer as a priority for prevention in different world regions: an evaluation using years of life lost. Int J Cancer. 2004;109:418-24.
7. Bosch FX, Brokerb TR, Formanc D, Moscickid AB, Gillisone ML, Doorbarf J, et al. Comprehensive control of human papilloma infections and related diseases. Vaccine. 2013;31S:F1-F31.
8. Crosbie EJ, Einstein MH, Franceschi S, Kitchener HC. Human papillomavirus and cervical cancer. Lancet. 2013;382:889-99.
9. Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV, Snijders PJ, Meijer CJ, International Agency for Research on Cancer Multicenter Cervical Cancer Study Group. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003;348:518-27.
10. Paavonen J, Jenkins D, Bosch FX, Naud P, Salmeron J, Wheeler CM, et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet. 2007;369:2161-70.
11. Paavonen J, Naud P, Salmeron J, Wheeler CM, Chow SN, Apter D, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet. 2009;374:301-31.
12. Villa LL, Costa RL, Petta CA, Andrade RP, Paavonen J, Iversen OE, et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Brit J Cancer. 2006;95:1459-66.
13. Harries J, Moodley J, Barone MA, Mall S, Sinanovic E. Preparing for HPV vaccination in South Africa: key challenges and opinions. Vaccine. 2009;27:38-44.
14. Becker-Dreps S, Otieno WA, Brewer NT, Agot K, Smith JS. HPV vaccine acceptability among Kenyan women. Vaccine. 2012;28:4864-67.
15. Ladner J, Besson MH, Hampshire R, Tapert L, Chirenje M, Saba J. Assessment of eight HPV vaccination programs implemented in lowest income countries. BMC Public Health. 2012;12:370.
16. Ladner J, Besson MH, Rodrigues M, Audureau E, Saba J. Performance of 21 HPV vaccination programs implemented in low and middle-income countries, 2009-2013. BMC Public Health. 2014;14:670.
17. Wigle J, Coast D, Watson-Jones D. Human papillomavirus (HPV) vaccine implementation in low and middle-income countries (LMICs): health system experiences and prospects. Vaccine. 2013;31(37):3811-7.
18. Steben M, Jeronimo J, Wittet S, LaMontagne SD, Ogilvie G, Jensen C, et al. Upgrading public health programs for Human Papilloamvirus Prevention and Control is possible in low - and middle-income countries. Vaccine. 2012;30S:F183-91.
19. Kane MA, Serrano B, Sanjosé S, Wittet S. Implementation of human papillomavirus immunization in the developing world. Vaccine. 2012;30S:F192-200.
20. WHO. Human papillomavirus vaccines: WHO position paper. WHO Weekly Epidemiol Record. 2009;84:117-32.
21. Blume S. Anti-vaccination movements and their interpretations. Soc Sci Med. 2006;62:628-42.
22. Becker-Dreps S, Otieno WA, Brewer NT, Agot K, Smith JS. HPV vaccine acceptability among Kenyan women. Vaccine. 2010;28(31):4864-7.
23. Coleman MA, Levison J, Sangi-Haghpeykar H. HPV vaccine acceptability in Ghana, West Africa. Vaccine. 2011;29(23):3945-50.
24. Woo YL, Omar SZ. Human papillomavirus vaccination in the resourced and resource-constrained world. Best Pract Res Clin Obstet Gynaecol. 2011;25(5):597-603.
25. Agosti JM, Goldie SJ. Introducing HPV vaccine in developing countries-key challenges and issues. N Engl J Med. 2007;356:1908-10.
26. Binagwaho A, Wagner CM, Gatera M, Karema C, Nutt CT, Ngabo F. Achieving high coverage in Rwanda’s national human papillomavirus vaccination programme. J Bull World Health Organ. 2012;90:623-8.
27. Fregnani JH, Carvalho AL, Eluf-Neto J, Ribeiro KC, Kuil LM, Da Silva TA, et al. A school-based human papillomavirus vaccination program in Barretos, Brazil: final results of a demonstrative study. PLoS One. 2013;8:e62647.
28. Watson-Jones D, Baisley K, Ponsiano R, Lemme F, Remes P, Ross D, Kapiga S, Mayaud P, de Sanjosé S, Wight D, Changalucha J, Hayes R. Human papillomavirus vaccination in Tanzanian schoolgirls: cluster-randomized trial comparing 2 vaccine-delivery strategies. J Inf Dis. 2012;206:678-86.
29. LaMontagne DS, Barge S, Le NT, Mugisha E, Penny ME, Gandhi S, et al. Human papillomavirus vaccine delivery strategies that achieved high coverage in low- and middle-income countries. J Bull World Health Organ. 2011;89:821-830B.
30. Friedman AL, Oruko KO, Habel MA, Kinsey FJ, Odhiambo F, Phlips-Howards PA, et al. Preaparing for human papillomavirus vaccine introduction in Kenya: implications from focus-group and interview discussions with caregivers and opinion leaders in Western Kenya. BMC Public Heath. 2014;14:855.
31. Paul P, Fabio A. Literature review of HPV vaccine delivery strategies: considerations for school and non-school based immunization program. Vaccine. 2014;32(3):320-6.
32. Sankaranarayanan R. Screening for cancer in low- and middle-income countries. Ann Glob Health. 2014;80(5):412-7.
33. Larson HJ, Brocard P, Garnett G. The India HPV-vaccine suspension. Lancet. 2010;376:572-3.